Применение Флуимуцила® (N-ацетилцистеина) при заболеваниях легких

1. Sheffner A.L. The reduction in vitro in viscosity of mucoprotein solution by a new mucolytic agent, N-acetylcysteine. Ann. N.Y. Acad. Sei. 1963; 106: 298-310.

2. Регистр лекарственных средств России. Энциклопедия лекарств. Ежегодный сборник. М.; 2002; вып. 9.

3. Ziment I. Acetylcysteine: a drug that is much more than a mucokinetic. Biomed. and Pharmacother. 1988; 42: 513-520.

4. De Caro L., Ghizzi A., Costa R. et al. Pharmacokinetics and bioavailability of oral acetylcysteine in healthy volunteers. Arzneimittel-Forsch. 1989; 39: 382-385.

5. Borgstrom L., Kagedal В., Paulsen О. Pharmacokinetics of N-acetylcysteine in man. Eur. J. Clin. Pharmacol. 1986; 31: 217-222.

6. De Vries N., De Flora S. N-acetyl-l-cysteine. J. Cell Biochem. 1993; 17F: S270-S277.

7. Issels R.D., Nagele A., Eckert K.G., Wilmanns W. Promotion of cystine uptake and its utilization for glutathione biosynthesis induced by cysteamine and N-acetylcy steine. Biochem. P h arm aco l. 1988; 37: 881-888.

8. De Flora S., Bennicelli C., Camoirano A. et al. In vivo effects of N-acetylcysteine on glutathione metabolism and on the biotransformation of carcinogenic and/or mutagenic compounds. Carcinogenesis 1985; 6: 1735-1745.

9. Nakata K., Kawase M., Ogino S. et al. Effects of age on levels of cysteine, glutathione and related enzyme activities in livers of mice and rats and an atempt to replenish hepatic glutathione level of mouse with cysteine derivatives. Mech. Ageing Dev. 1996; 90: 195-207.

10. Kelly G.S. Clinical applications of N-acetylcysteine. Alt. Med. Rev. 1998; 3 (2): 114-127.

11. Pratt S., Ioannides C. Mechanism of the protective action of N-acetylcysteine and methionine against paracetamol toxicity in the hamster. Arch. Toxicol. 1985; 57: 173-177.

12. Baier J.E., Neumann H.A., Moeller T. et al. Radiation protection through cytokine release by N-acetylcysteine. Strahlenther. Onkol. 1996; 172: 91-98.

13. Devlin J., Ellis A.E., McPeake J. et al. N-acetylcysteine improves indocyanine green extraction and oxygen transport during hepatic dysfunction. Crit. Care Med. 1997; 25: 236-242.

14. Iravani M. E. et al. N-acetylcysteine and mucociliary activity in mammalian airways. DrugRes. 1987, 28: 250-254.

15. Davis S.S., Deverell L.C. Rheological factors in mucociliary clearance: the assessment of mucotropic agents using in vitro model. Mod. Probl. Paediatr. 1977; 19: 207-232.

16. Sheffner A.L. The reduction in vitro in viscosity of mucoprotein solution by a new mucolytic agent, N-acetylcysteine. Ann. N.Y. Acad. Sei. 1963; 106: 298-310.

17. Allegra L. et al. Compromissione del trasporto mucociliare indottadall'ozono e sua prevenzione con N-acetilcisteina. Am. J. Med. 1984; 91 (suppl. 3C ): 67-71.

18. Mereto G.C. et al. Alveolar surfactant in lungs of operated patients after acetylcysteine treatment. Eur. J. Respir. Dis. 1980; 61 (suppl. Ill): 160-161.

19. Herwaarden C.L.A., Bast A., Dekhuijzen P.N.R. The role of N-acetylcysteine in the treatment of COPD: experimental studies. In: Herwaarden C.L.A. et al., eds. COPD: diagnosis and treatment. Amsterdam: Excerpta Medica; 1996. 118-122.

20. Eklund A., Eriksson O., Hakansson L. et al. Oral N-acetylcystein reduces selected humoral markers of inflammatory cell activity in BAL fluid from healthy smokers: correlation to effects on cellular variables. Eur. Respir. J. 1988; 1: 832-838.

21. Liden M., Wieslander E., Eklund A. et al. Effects of oral N-acetylcysteine on cell content and macrofage function in bronchoalveolar lavage from healthy smokers. Ibid. 645-650.

22. Bergstrand H., Bjornson A., Eklund A. et al. Stimuli-induced Superoxide radical generation in vitro by human alveolar makrophages from smokers: modulation by N-acetylcysteine treatment in vivo. J. Free Radic. Biol. Med. 1986; 2: 119-127.

23. Vecchiarelli A. et al. Macrophage activation by N-acetylcysteine in COPD patients. Chest 1994; 105: 806-811.

24. Oddera S. et al. N-acetylcysteine enhances in vitro the in tracellular killing of Staphylococcus aureus by huma nalveolar macrophages and blood polymorphonuclear leukocytes and partially protects phagocytes from self-killing. J. Lab. Clin. Med. 1994; 124: 293-301.

25. Riise G.C. et al. The in trabronchial microbial flora in chronic bronchitis patients: a target for N-acetylcysteine therapy. Eur. Respir. J. 1994; 7: 94-101.

26. Niederman M.S., Rafferty T.D., Sasaki C.T. et al. Am. Rev. Respir. Dis. 1983; 127: 85-90.

27. Балясинская Г.Л., Минасян B.C., Качкаева Е.Д. Опыт применения ринофлуимуцила и флуимуцила антибиотика при лечении синуситов у детей. В кн.: Богомильский М.Р. (ред.) Актуальные вопросы отоларингологии детского возраста и фармакотерапии болезней ЛОP-органов. Интернет-публикация, сайт www.zarnbon.ru.

28. Grassi С. et al. Use of a modified throm boelastograph to evaluate effects of acetylcysteine on sputum. Respiration 1977; 34: 100-104.

29. Lieberman J. Measurement of sputum viscosity in a cone-plate viscometer. Am. Rev. Respir. Dis. 1968; 97: 662-672.

30. Todisco T. et al. Effects of N-acetylcysteine in subjects with slow pulmonary mucociliary clearance. Eur. J. Respir. Dis. 1985; 66 (suppl. 139): 136-141.

31. Olivieri A . Improvement of mucociliary transport in smokers by mucolytics. Ibid. 142-145.

32. Millar A.B. et al. Effects of oral N-acetylcysteine onmucus clearance. Br. J. Dis. Chest 1985; 79: 262-266.

33. Webb W.R. et al. Acetylcysteine as a mucolytic agent in clinical practice. Clin. Med. 1964; 9: 1531-1539.

34. Perruchoud A. et al. Atelectasis of the lung: bronchoscopic lavage with acetylcysteine. Experience in 51 patients. Eur. J. Respir. Dis. 1980; 61 (suppl. Ill): 163-168.

35. Дуганов В.К., Дмитриев Ю.К., Яськов А.М., Филатова Е.Г. Лечебная фибробронхоскопия при острых бронхолегочных заболеваниях и обострении хронических бронхолегочных заболеваний. Интернет публикация. 2001; сайт: www.zambon.ru.

36. Волков И.К. Диагностическая и терапевтическая эффективность бронхоскопии при хронических и рецидивирующих бронхолегочных заболеваниях у детей: Автореф . дис. ... д-ра мед. наук. М .; 1993.

37. Grassi С. et al. Clinical evaluation of systemic acetylcysteine by different routes of administration. Curr. Ther. Res. 1973; 15: 165-179.

38. Henneghien C. Study of N-acetylcysteine (NAC) by oral or intravenous administration in chronic bronchitis. Ibid. 1983; 34: 750-756.

39. Menozzi D., Debbia F. Sull'impiego dell'acetilcisteina per via orale nella pratica chirurgica. Minerva Chir. 1974; 29: 851-858.

40. Bellomo G. et al. Studio comparativo dell'efficacia dell'acetilcistein a per via orale ed intramuscolare nelle affezioni respiratorie acute in pediatría. Minerva Pediatr. 1973; 25: 844-849.

41. Biscatti G. et al. Ricerca controllata sugli effetti clinici dell'acetilcistein a per via orale nelle infezioni respiratorie in pediatría. Ibid. 1972; 24: 1075-1084.

42. Versireaten J.M. Mucolytic treatment in chronic obstructive pulmonary disease: double-blind comparative clinical trial with N-acetylcysteine, bromhexine and placebo. Acta Tuberc. P n eu m o l. B elg. 1979, 70: 71-80.

43. Aylward M. et al. Clinical evaluation of acetylcysteine in the treatment of patients with chronic obstructive bronchitis: a balance double-blind trial with placebo control. Eur. J. Respir. D is. 1980; 61 (suppl. 111): 81-89.

44. Tattersall A.B. et al. Acetylcysteine in chronic bronchitis. A study in general practice. J. Intern. Med. Res. 1983; 11: 279-284.

45. Tattersall A.B. et al. Irish general practice study of acetylcysteine in chronic bronchitis. Ibid. 1984; 12: 96-101.

46. Multicenter Study Group. Long-term oral acetylcysteine in chronic bronchitis. A double-blind controlled study. Eur. J. Respir. Dis. 1980; 61 (suppl. 111): 93-108.

47. British Thoracic Society Research Comittee. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax 1985; 40: 832-835.

48. Sanguinetti M. et al. To evaluate the effectiveness of NAC in preventing the recurrence of acute bronchitis in BPCO patients. In: Associazione Italiano Pneumologi Ospedalieri. XXXIII National Congess. Turin; 1995. 75.

49. Grandjean E.M., Berthet P., Ruffmann R. et al. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: ameta-analysis of published double-blind, placebo-controlled clinical trials. Clin. Ther. 2000; 22: 209-221.

50. Hansen N.C.G., Skriver A., Brorsen-Riis L. et al. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med. 1994; 88: 531-535.

51. Чучалин А.Г. (ред.) Базисная терапия N-ацетилцистеином хронических неспецифических заболеваний легких у ликвидаторов последствий аварии на Чернобыльской атомной электростанции: Метод, рекомендации. М .; 1999.

52. Stey C., Steurer J., Bachmann S. et at. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur. Respir. J. 2000; 16: 253-262.

53. Boman G., Bäcker ULarsson S. et al. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for pulmonary diseases. Eur. J. Respir. Dis. 1983; 64: 405-415.

54. Parr G.D., Huitson A. Oral fabrol (oral N-acetylcysteine) in chronic bronchitis. Br. J. Dis. Chest 1987; 81: 341-348.

55. van Zandwijk N., Dalesio O., Pastorino U. et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. J. Natl. Cancer Inst. 2000; 92: 977-986.

56. Riise G.C., Larsson S., Larsson P. et al. The intrabronchial microbial flora in chronic bronchitis patients: a target for N-acetylcysteine therapy? Eur. Respir. J. 1994: 7: 94-101.

57. Lundback B., Lindstrom M., Andersson S. et al. Possible effect of acetylcysteine on lung function. Ibid. 1992: 5 (suppl. 15): 895.

58. Snow V. et al. The evidence base for management of acute exacerbation of COPD. Chest 2001; 119 (4): 1185-1189.

59. Bernard G.R., Wheeler A.P., Arons M.M. et al. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Ibid. 1997; 112: 164-172.

60. Behr J., Maier K., Degenkolb В. et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am. J. Respir. Crit. Care Med . 1997; 156: 1897-1901.

61. De Flora S. et al. Attenuation of influenza-like symptomatology and improvement of cell-mediated with long term NAC treatment: report of the NACIS study. Eur. Respir. J. 1997; 10: 1535-1541.

62. Chodosh S. Safety of acetylcysteine. Eur. J. Respir. Dis. 1980; 61 (suppl. 111): 169.

63. Hodson M.E. et al. Meconium ileus equivalent in adults with cystitis fibrosis of pancreas. A report of cases. Br. Med. J. 1976; 2: 790-791.

64. Maini U. et al. Controlled endoscopic study on gastroduodenal safety of acetylcysteine after oral administration. Eur. J. Respir. Dis. 1980; 61 (suppl.111) : 147-150.

65. Grater W.C., Cato A. Double-blind study of acetylcysteine-isoproterenol in n o n-hospitalized patients patient with asthma. Curr. Ther. R es. 1973; 15: 660-671.

66. Stiksa G. et al. Effects of inhaled N-acetylcysteine in combination with terbutaline. Eur. J. Respir. Dis. 1984; 65: 278-282.

67. Minette A. C linical effects of mucolytic associated with bronchodilators in treating exacerbation of chronic bronchitis in coal miners. Rev. Inst. Hyg. Mines 1982; 37: 112-119.

68. Lualdi P., Marca G. Effect de la N-acetylcysteine orale sur la biodisponobilté des antibiotic schagez l'homme. Ars Med. (Liestal) 1979; 34: 761-769.

69. Paulsen О. et al. No effect of oral N-acetylcysteine on the bioavailability of erythromycin and bacampicillin. Eur. Respir. J. 1988; 1: 171-175.

70. Кадырова P. Терапевтическая эффективность муколитических препаратов при разных методах их введения в комплексном лечении муковисцидоза у детей : Автореф . дис. ... канд. мед. наук. М .; 1984.

71. Капранов Н.И., Волков И.К., Зоирова Р. Исследование вязкости мокроты для оценки эффективности муколитической терапии детей больных муковисцидозом. Вопр. охр. мат. 1985; 2: 12-15.

72. Alonso Е.М., Sokol R.J., Hart J. et al. Fulminant hepatitis associated with centrilobular hepatic necrosis in young children. J. Pediatr. 1995; 127: 888-894.

73. Penna A.C., Dawson K.P., Penna C.M . Is prescribing paracetamol "prorenata" acceptable? J. Paediatr. Child Hlth 1993; 29: 104-106.

74. Litovitz T.L., Klein-Schwartz W., Dyher K.S. et al. 1997 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am. J. Emerg. Med. 1998; 16: 443-497.

75. Acetaminophen toxicity in children. American Academy of Pediatrics. Committee on drugs. Pediatrics 2001 ; 108 (4): 1020-1024.